Last reviewed · How we verify
Robitussin Extra Strength Chest Congestion — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Robitussin Extra Strength Chest Congestion (Robitussin Extra Strength Chest Congestion) — Reckitt Benckiser Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Robitussin Extra Strength Chest Congestion TARGET | Robitussin Extra Strength Chest Congestion | Reckitt Benckiser Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Robitussin Extra Strength Chest Congestion CI watch — RSS
- Robitussin Extra Strength Chest Congestion CI watch — Atom
- Robitussin Extra Strength Chest Congestion CI watch — JSON
- Robitussin Extra Strength Chest Congestion alone — RSS
Cite this brief
Drug Landscape (2026). Robitussin Extra Strength Chest Congestion — Competitive Intelligence Brief. https://druglandscape.com/ci/robitussin-extra-strength-chest-congestion. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab